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Abstract
Background: Multiple myeloma (MM) is a B-cell malignancy that is largely incurable and is characterized by the
accumulation of malignant plasma cells in the bone marrow. Apigenin, a common flavonoid, has been reported to
suppress proliferation in a wide variety of solid tumors and hematological cancers; however its mechanism is not
well understood and its effect on MM cells has not been determined.
Results: In this study, we investigated the effects of apigenin on MM cell lines and on primary MM cells. Cell
viability assays demonstrated that apigenin exhibited cytotoxicity against both MM cell lines and primary MM cells
but not against normal peripheral blood mononuclear cells. Together, kinase assays, immunoprecipitation and
western blot analysis showed that apigenin inhibited CK2 kinase activity, decreased phosphorylation of Cdc37,
disassociated the Hsp90/Cdc37/client complex and induced the degradation of multiple kinase clients, including
RIP1, Src, Raf-1, Cdk4 and AKT. By depleting these kinases, apigenin suppressed both constitutive and inducible
activation of STAT3, ERK, AKT and NF-B. The treatment also downregulated the expression of the antiapoptotic
proteins Mcl-1, Bcl-2, Bcl-xL, XIAP and Survivin, which ultimately induced apoptosis in MM cells. In addition,
apigenin had a greater effects in depleting Hsp90 clients when used in combination with the Hsp90 inhibitor
geldanamycin and the histone deacetylase inhibitor vorinostat.
Conclusions: Our results suggest that the primary mechanisms by which apigenin kill MM cells is by targeting the
trinity of CK2-Cdc37-Hsp90, and this observation reveals the therapeutic potential of apigenin in treating multiple
myeloma.
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Background
Multiple myeloma (MM) is a B-cell malignancy charac-
terized by the accumulation of malignant plasma cells in
the bone marrow. Despite the use of conventional or
high-dose chemotherapy or autologous stem-cell trans-
plantation, tumor cells invariably generate a resistance
to the various treatments. Chemoresistance of MM cells
remains the primary obstacle in developing a satisfactory
treatment [1]. Therefore, to improve outcomes and
extend the length of survival, the establishment of more
effective treatments that can overcome or circumvent
chemoresistance has become a priority.
Casein kinase 2 (CK2) is a ubiquitous cellular serine-
threonine kinase with a broad spectrum of substrates.
CK2 participates in the regulation of multiple biologic
processes and plays an important role in regulating mul-
tiple cellular functions, including transcription, transla-
tion, signal transduction and metabolism [2,3]. The
expression and activity of CK2 are frequently elevated in
cancer cells, which provides a growth advantage because
its activity counteracts apoptosis and sustains the cell
cycle [4,5]. It has been shown that MM cell lines and
* Correspondence: yuxd@nic.bmi.ac.cn
1Department of Stress Medicine, Institute of Basic Medical Sciences,
Cognitive and Mental Health Research Center, Beijing, 100850, China
Full list of author information is available at the end of the article
Zhao et al. Molecular Cancer 2011, 10:104
http://www.molecular-cancer.com/content/10/1/104
© 2011 Zhao et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.highly purified malignant plasma cells in patients with
MM expressed higher protein and CK2 activity levels
than normal plasma cells and B lymphocytes [6]. In this
regard, using siRNA to inhibit CK2 activity induced
apoptosis and enhanced the cytotoxic effect of melpha-
lan on MM cells. It was proposed that CK2 might play
a pivotal role in controlling survival and sensitivity to
chemotherapeutics of MM cells [6]. The exact mechan-
isms governing the pleiotropic activity of CK2 have not
been well defined. However, some recent studies have
demonstrated that CK2 controls Hsp90 chaperone
machinery by phosphorylating a kinase-targeting mole-
cular co-chaperone, Cdc37 [7,8].
Among Hsp90 co-chaperones, Cdc37 is unique
because it interacts with a subset of client kinase pro-
teins within Hsp90 complexes and plays a specialized
role as a primary partner in kinome maintenance [9].
C d c 3 7p l a y sar o l ei np r o t e i nk i n a s eq u a l i t yc o n t r o ln o t
only by protecting nascent polypeptide chains from
degradation and by promoting posttranslational matura-
tion [10]. CK2-mediated phosphorylation of Cdc37 on a
conserved Ser13 in the N-terminal region is important
for efficient binding to client kinases and for recruiting
Hsp90 to the kinase-Cdc37 complex [7,8]. Therefore,
CK2 activity also depends on Cdc37; there is a positive
feedback loop between CK2 and Cdc37 which positively
regulates multiple protein kinases [11]. Hsp90 binds to
and protects CK2 from self-aggregation and enhances
its kinase activity [12]. Strikingly, several crucial antican-
cer targets, including EGFR, PDGFR, Aurora B, Src, Raf-
1, AKT, IKK, Cdc2, Cdk2, Cdk4, and Cdk6 are Cdc37
client kinases http://www.picard.ch/downloads/Cdc37in-
teractors.pdf. Because the function of Hsp90/Cdc37
determines the stability and activity of these kinases, the
dependency of the cancer cell kinome on Hsp90/Cdc37
makes the CK2-Cdc37-Hsp90 trinity a promising anti-
cancer drug target [13].
Cdc37 is overexpressed in several types of cancers,
including multiple myeloma [9]. Previous studies have
shown that RNA interference-mediated downregulation
of Cdc37 enhances the cytotoxic effects of Hsp90 inhibi-
tors in prostate cancer cells and colon cancer cells by
reducing client kinase activity and decreasing survival
signaling [14,15]. Treating cells with 4, 5, 6, 7-Tetrabro-
mobenzotriazole (TBB), which is a specific chemical
inhibitor of CK2, induces a decline in phosphorylation
of Cdc37 and decreases the intracellular levels of
Cdc37-dependent protein kinases [8]. However, an eva-
luation of the strategies of killing cancer cells by inhibit-
ing CK2-dependent phosphorylation of Cdc37 has not
been reported.
The flavonoid apigenin is abundant in common fruits
and vegetables. Apigenin has gained attention because
it has notable anti-inflammatory, antioxidant and anti-
carcinogenic properties [16]. Apigenin has been shown
to be remarkable in inhibiting growth, arresting cell
cycle and inducing apoptosis of human prostate can-
cer, breast cancer and leukemia [17-21]. Possible
mechanisms mediating its anticancer effects include
modulation of various kinase activities [17], inactiva-
tion of NF-B [18], inhibition of proteasomal activity
[19] and induction of proteasomal degradation of the
Her2/neu proteins [20]. As a selective CK2 kinase inhi-
bitor, apigenin has been reported to induce cell death
to a greater extent in CK2a-high AML than in CK2a-
low AML or normal BM samples [21]. However, the
detailed mechanism by which targeting CK2 leads to
apoptosis and inactivation of survival signals has not
been defined. Given that MM cells also exhibit high
CK2 activity, it was of interest to determine the ability
of apigenin to kill MM cells. In the present study, we
have investigated the effects of apigenin on MM cell
lines and purified primary MM cells. We found that
apigenin inhibited the proliferation of MM cells, and
induced apoptosis of MM cells through the suppres-
sion of CK2 kinase and the reduction of Cdc37 phos-
phorylation. These effects disrupted the Hsp90
chaperone function and downregulated multiple client
kinase proteins, and as a consequence, induced apop-
tosis in MM cells.
Methods
Reagents and antibodies
Apigenin, MG132, Geldanamycin and a-tubulin anti-
body were obtained from Sigma-Aldrich (St Louis, MO,
USA), and suberoylanilide hydroxamic acid (SAHA or
Vorinostat) was donated by AstraZeneca (Macclesfield,
S K ,U K ) .T h e s er e a g e n t sw e r ed i s s o l v e di nD M S O( l e s s
than 0.1%, v/v). Recombinant human (rh) IL-6 and
rhIGF-1 were purchased from PeproTech (Rocky Hill,
NJ, USA). Antibodies against phospho-AKT (Ser473),
AKT, phospho-ERK (Thr202/Tyr204), ERK, phospho-
STAT3 (Tyr705), STAT3, phospho-IB-a (Ser32), phos-
pho-PDK1, PDK1, phospho-MEK, MEK, phospho-IKK,
poly (ADP-ribose) polymerase (PARP), and XIAP were
obtained from Cell Signaling Biotechnology (Beverly,
MA, USA). Antibodies against Survivin, Mcl-1, IKK and
Cdc37 were purchased from Santa Cruz Biotechnology
( S a n t aC r u z ,C A ,U S A ) .A n t i - b-actin, phosphoserine,
CK2a antibodies and tetrabromobenzotriazole (TBB)
were obtained from Calbiochem (San Diego, CA, USA).
Anti-Raf-1, Bcl-2, Bcl-xL and Cdk4 antibodies were pur-
chased from BD Biosciences (San Diego, CA, USA). The
anti-Src antibody was purchased from Upstate Biotech-
nology (Lake Placid, NY, USA). The anti-Hsp90 anti-
body was obtained from Stressgen Biotechnologies
(Victoria, BC, Canada). The anti-RIP1 antibody was pur-
chased from Abcam (Cambridge, MA, USA).
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The human MM cell lines (U266 and RPMI 8226) were
obtained from the American Type Culture Collection
(ATCC; Rockville, MD) and cultured in RPMI 1640
medium containing 10% heat-inactivated fetal bovine
serum (FBS) and 100 U/ml penicillin-streptomycin. The
human cervical carcinoma cell line (HeLa) were cultured
in DMEM medium with 10% FBS. Bone marrow sam-
ples were obtained from patients with MM that under-
went treatment at the General Hospital of PLA (Beijing,
China), and approval was obtained from the hospital
institutional review board for these studies. Informed
consent was obtained from all patients in accordance
with the Declaration of Helsinki. The CD138
+ cells were
separated by immunomagnetic bead selection (Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany). The purity
of isolated CD138-positive plasma cells was approxi-
mately 95% as assessed by flow cytometry using phy-
coerythrin (PE)-conjugated monoclonal CD138
antibodies. To generate peripheral blood mononuclear
cells (PBMCs), 5 ml of whole blood was collected from
five healthy donors. PBMCs were enriched by density
centrifugation over Ficoll-Paque density gradient. The
mononuclear cell fraction was collected and washed
three times in sterile PBS and was immediately used in
the cytotoxicity assays.
Cell Viability Assay
The cell viability was determined by the 3-(4, 5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)- 2-(4-
sulfophenyl)-2H-tetrazolium (MTS) assay according to
the manufacturer’s instructions (CellTiter96 Aqueous
Non Radioactive Cell proliferation Assay kit; Promega,
Madison, WI, USA). MM cell lines were cultured in
complete medium containing the vehicle DMSO (con-
trol, less than 0.1%, v/v) or complete medium supple-
mented with various concentrations of apigenin or TBB
for 24 h and 48 h. At the end of the incubation period,
20 μl of the combined MTS/PMS solution was added
into each well of the 96-well plate. Following 4 h of
incubation at 37°C and 5% CO2, absorbance was
detected at a wavelength of 490 nm. The results are pre-
sented as means ± SD from three independent experi-
ments. Inhibition graphs were plotted using mean values
obtained from each concentration relative to control
values.
Cell cycle analysis
Log-phase U266 and RPMI 8226 cells were seeded in 6-
well plates and treated with varying dose of apigenin or
vehicle DMSO for 24 h. The cells were harvested,
washed with PBS and fixed with 70% ethanol containing
1% FBS at -20°C overnight. After an additional washing
step, cells were incubated with RNase A (20 μg/ml) at
37°C for 30 min, stained with propidium iodide (PI, 100
μg/ml) for 10 min, and analyzed by flow cytometry.
Apoptosis assay
Apoptosis was determined with the Annexin-V-FLUOS
staining kit (Roche, Indianapolis, IN, USA) according to
the manufacturer’s instructions. Briefly, the vehicle
DMSO control and the apigenin-treated cells were col-
lected by centrifugation and were washed one time with
PBS. The cells were subsequently stained with fluores-
cein and PI for 15 min at room temperature and ana-
lyzed by flow cytometry.
CK2 kinase activity assay
CK2 kinase activity in cell lysates was measured by
using the Casein Kinase-2 Assay Kit (Upstate Bio-
technologies, Temecula, CA, USA) as described before
[21]. Briefly, 20 μg whole-cell lysates were tested in
Assay Dilution Buffer I (ADBI) plus with 200 μMs u b -
strate peptide (RRRDDDSDDD), 2 μMP K Ai n h i b i t o r
peptide(PKI-[6-22]-NH2), and 100 μCi [g-
32P] ATP. The
reaction mixtures were incubated with agitation for 10
min at 30°C. Reactions were stopped by addition of 40%
trichloroacetic acid (TCA). Samples (25 μl) were then
transferred onto phosphocellulose filter paper square
P81, and the radiolabeled substrate was allowed to bind
to the paper for 30 sec. The paper was immersed in
0.75% phosphoric acid and mixed gently on a rotator;
followed by washing six times with 0.75% phosphoric
acid and one wash with acetone for 1 min. Radioactivity
incorporated into the substrate peptide was determined
by scintillation counting.
Immunofluorescence analysis
The vehicle-only control and apigenin-treated cells were
fixed for 10 min in PBS containing 4% paraformalde-
hyde and permeabilized with 0.25% Triton X-100 for 10
min. After washing 3 times with PBS, the cells were
immersed in 1% bovine serum albumin (BSA) for 30
min and were incubated with primary anti-CK2a anti-
body (1:50) overnight at 4°C. After additional washing
with PBS, the cells were incubated with secondary anti-
body conjugated with FITC for 1 h in the dark at room
temperature. The cells were examined either by flow
cytometry or by fluorescent microscopy at total 1000×
magnification under immersion oil using a LSM 510
META ZEISS fluorescent microscope. The fluorescence
intensity of CK2a protein was quantified using Soft-
WoRx Explore 1.2 (Applied Precision, Issaquah, USA).
RNA interference
Small interfering RNA (siRNA) oligonucleotides were
synthesized by GeneChem Co., Ltd (Shanghai, China).
The sequence for CK2a was 5’-GAUGACUACCAGCUG
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UUCUCCGAACGUGUCACGUTT-3’. The siRNAs were
introduced into HeLa and MM cells by RNAiFect Trans-
fection Reagent or electroporation respectively. HeLa cells
were transfected with 40 nM siRNA using the RNAiFect
Transfection Reagent (Qiagen, Germany) according to the
manufacturer’s instructions. Log-phase U266 and RPMI
8226 cells were harvested, washed once and resuspended
in serum-free RPMI1640 medium at a concentration of 1
×1 0
7/ml. Control siRNA (75 pM) or CK2a-siRNA (75
pM) was added to 200 μl cell suspension. Next, the mix
was transferred directly into a 2 mm gap electroporation
cuvette and was electroporated with an Electro Square
Porator ECM830 (BTX, San Diego, CA) at 250 V and 500
μs. Immediately after the pulse, the cell suspension was
incubated on ice for 10 min, and the cells were resus-
pended in complete medium for 48 h. The cells were har-
vested and subjected to western blotting with the
indicated antibodies.
Immunoprecipitation and western blotting
Immunoprecipitation experiments were performed as
previously described [22]. Briefly, samples (500 μgo f
total protein) were incubated with 2 μg primary anti-
body overnight at 4°C, after which 20 μl of protein A/G-
Plus-Agarose (Santa Cruz Biotechnology, CA, USA) was
added to the mixture and incubated for 2 h at 4°C. The
immunoprecipitated protein complexes were washed
one time with lysis buffer and twice with ice-cold PBS.
After discarding the supernatant, the antibody-protein
complexes were resuspended in 20 μl Laemmli Sample
Buffer (Bio-Rad Laboratories, CA, USA) and boiled for 5
m i n .T h ee n t i r es a m p l ew a ss e p a r a t e db y1 0 %S D S -
PAGE and assayed by protein immunoblotting.
For western blotting, vehicle control and apigenin-
treated cells were lysed in Laemmli Sample Buffer. After
electrophoresis, the proteins were electrotransfered to
PVDF membranes, blotting with antibodies indicated
and visualized by SuperSignal West Dura Extended
Duration Substrate (PIERCE, Rockford, IL, USA).
Statistical analysis
ANOVA was employed for comparisons across multiple
groups. The mean of the control was compared with the
mean of each individual treatment group by Dunnett’s
test. All statistical analyses were performed with the
Prism 5 software (GraphPad Software Inc., San Diego,
CA). Significance was set at p < 0.05.
Results
Apigenin inhibits CK2 kinase activity and induces growth
inhibition and cell cycle arrest in MM cells
Initially, we investigated the effects of apigenin on CK2
kinase activity and expression level and compared these
effects with that of TBB, which is a known selective CK2
inhibitor [23]. The results showed that in accordance
with TBB, apigenin suppresses CK2 kinase activity (Fig-
ure 1A), and reduces CK2a protein levels (Figure 1B) in
both U266 and RPMI 8226 cells in a dose-dependent
manner. Apigenin and TBB-induced suppression of CK2
was correlated with a dose-dependent decline in MM cell
viability (Figure 1C, D), the magnitude of cell prolifera-
tion inhibition was greater in U266 cells compared to
RPMI 8226 cells. We subsequently evaluated the effect of
apigenin and TBB on cell cycle distribution using flow
cytometry. Compared to vehicle-only treated controls,
the apigenin and TBB treatment resulted in an obvious
arrest of cells in G2/M phase after 24 h. The increase in
cell number in the G2/M cell population was accompa-
nied by a concomitant decrease in the number in S phase
and G0/G1 phases of the cell cycle. Treatment with api-
genin led to a dose-dependent accumulation of sub-G1
cells in both U266 and RPMI 8226 cells, thereby indicat-
ing that apigenin induces MM cell death, even at rela-
tively low doses (30 μM), whereas TBB only induced
minor cell death at 75 μM (Figure 1E, F).
Apigenin induces apoptosis and downregulates the
expression of antiapoptotic proteins in MM cells
Next, we treated U266 and RPMI 8226 cells with api-
genin for 24 h and analyzed apoptotic cell death using
the Annexin V-FLUOS staining Kit. The results revealed
a dose-dependent induction of early apoptotic or necro-
tic/late apoptotic cell death in these two cell lines (Fig-
ure 2A). Compared to RPMI 8226 cells, U266 cells
showed more cell death, which was consistent with the
results of the cell viability assay. Western blot analysis
revealed that apigenin caused a dose-dependent decrease
in the expression of multiple antiapoptotic proteins,
including Mcl-1, Bcl-2, Bcl-xL, XIAP and Survivin. The
PARP precursor exhibited a similar reduction, which
was accompanied by an increase in the level of its
cleaved fragments (Figure 2B). These data indicate that
apigenin induced apoptosis in MM cells.
Apigenin suppresses constitutive and inducible activation
of STAT3, AKT, ERK and NF-B in MM cells
To investigate further the mechanisms involved in api-
genin-induced cell death, we assessed changes in the
cellular survival pathways of MM cells. Western blotting
results showed that high doses of apigenin decreased
the levels of phosphorylated ERK, AKT, STAT3 and
IB-a; the total AKT protein was also decreased (Figure
3A). We also examined the phosphorylation of PDK,
MEK and IKK, which are upstream kinase of AKT, ERK
and IB, and found that the phosphorylation levels of
these kinases were also reduced to varying degrees (Fig-
ure 3B). Unlike RPMI 8226 cells, U266 cells are known
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Page 4 of 14Figure 1 Apigenin inhibits CK2 kinase activity and induces growth inhibition and cell cycle arrest in MM cells. (A) CK2 kinase activity
was detected in U266 and RPMI 8226 cells exposed to TBB or apigenin for 24 h. Results from 1 of 3 different experiments are shown; data are
means ± SD. *Significant difference from control by ANOVA, *p < 0.05, **p < 0.01. (B) CK2a protein levels were detected by western blot analysis
in both cell lines treated with different doses of apigenin or TBB for 24 h, and the levels of b-actin serves as the loading control. (C) and (D)
U266 and RPMI 8226 cells were grown for 24-48 h in the absence or presence of increasing concentrations of apigenin or TBB respectively. Cell
growth inhibition was measured by MTS and is expressed as a percentage of vehicle-treated control; results are presented as means ± SD of
three independent experiments. *Significant difference from control by ANOVA, **p < 0.01. (E) and (F) Cell cycle analysis by flow cytometry after
apigenin or TBB treatment for 24 h respectively in U266 and RPMI 8226 cells.
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thereby forming an autocrine loop that can sustain
autonomous growth [24]. To obtain optimal inhibition
of MM proliferation, it is important to block extrinsic
signal activation. After a 12 h starvation, we treated
U266 cells with IL-6 or IGF-1 in the presence or
absence of 90 μM apigenin. As shown in Figure 3B, api-
genin completely blocked IL-6-induced activation of
STAT3 and IGF-1-induced activation of AKT and par-
tially inhibited IGF-1-induced activation of ERK. These
data indicated that apigenin inhibits not only intrinsic
cellular survival pathways but also blocks extrinsic cyto-
kine-induced signal transduction.
Apigenin reduces Cdc37 phosphorylation, disassociates
Hsp90/Cdc37/kinase complexes and degrades Hsp90/
Cdc37 client proteins
Previous studies have shown that CK2-mediated Ser13
phosphorylation of Cdc37 is essential for the Cdc37 co-
chaperone function involved in recruiting multiple
Figure 2 Apigenin induces apoptosis and downregulates the expression of antiapoptotic proteins in MM cells. (A) U266 and RPMI 8226
cells were treated with apigenin for 24 h, apoptotic cell death was detected by staining cells with the Annexin V-FLUOS kit and analyzed by
flow cytometry. (B) U266 and RPMI 8226 cells were treated with increasing doses of apigenin for 24 h, and the antiapoptotic proteins were
detected by western blot analysis using the indicated antibodies; b-actin was used as a loading control.
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results reported above, we postulated that apigenin may
exert its effect through inhibiting CK2-mediated Cdc37
phosphorylation, and thereby indirectly disrupting Hsp90
chaperone function. To evaluate this hypothesis, we
immunoprecipitated Cdc37 and probed blots with anti-
phosphoserine, anti-Hsp90, and anti-Cdk4 antibodies to
evaluate the phosphorylation of Cdc37 and to detect the
association between Cdc37 and its client proteins. Cells
were treated with apigenin or TBB (positive control). As
shown in Figure 4A, apigenin and TBB decreased the
phosphorylation of Cdc37, and the binding between
Cdc37 and Hsp90 or its client, Cdk4, indicating that the
Hsp90/Cdc37/Cdk4 chaperone complex had been disasso-
ciated. To further confirm the effect of apigenin on the
Hsp90/Cdc37 chaperone function, additional client pro-
teins were assessed by western blot analysis. The results
showed that apigenin induced a dose-dependent degrada-
tion of RIP1, Raf-1, Src and Cdk4 kinases (Figure 4B).
Apigenin-induced proteasome-dependent degradation of
Hsp90/Cdc37 client proteins is correlated with inhibition
of CK2
To confirm further that apigenin disrupts the Hsp90/
Cdc37 chaperone function via inhibiting CK2; we uti-
l i z e dH e L ac e l l sa n dc o m p a r e dt h ee f f e c t so fa p i g e n i n
and TBB on CK2a, RIP1, Raf-1 and Cdk4 proteins
levels. As depicted in Figure 5A, both apigenin and TBB
induced a reduction in CK2a and the degradation of
Hsp90Cdc37 client proteins in a dose-dependent man-
ner. These effects are quite similar to those observed in
U266 and RPMI8226 cells (Figure 4B). Using siRNA to
limit CK2a expression also led to the degradation of
RIP1, Raf-1 and Cdk4 proteins in both HeLa cells and
the two MM cell lines (Figure 5B, C). In addition, degra-
dation was completely blocked by treatment with the
proteasome inhibitor MG132, indicating that the protea-
some system was responsible for the apigenin-induced
client protein degradation (Figure 5D).
Figure 3 Apigenin suppresses constitutive and inducible activation of STAT3, AKT and ERK in MM cells. In (A) and (B), U266 and RPMI
8226 cells were treated with increasing doses of apigenin for 24 h, and the signaling proteins were detected by western blot analysis using the
indicated antibodies. In (C) and (D), U266 cells were deprived of serum for 12 h and were treated with rhIL-6 (10 ng/ml) or rhIGF-1 (50 ng/ml)
for the indicated times in the presence or absence of apigenin (90 μM). Whole-cell lysates were subjected to western blot analysis using the
indicated antibodies.
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siRNA compromised the maturation of Hsp90/Cdc37
clients, mediated an increased loss of proteins required
for growth and survival and enhanced the sensitivity of
cancer cells to Hsp90 inhibitors [14,15]. We examined
whether the apigenin-mediated inhibition of the Cdc37
chaperone function might have similar effects when
coupled with reagents that affected Hsp90 function. We
treated U266 cells with 30 μM apigenin alone or in
combination with 0.2 μM geldanamycin (GA), a known
Hsp90 inhibitor, or with 1 μMS A H A ,w h i c hi sa n
HDAC inhibitor that inhibits Hsp90 via enhancing its
acetylation [25,26]. All of the reagents were used at
levels below their cytotoxic concentrations. The result
showed that the combination of apigenin with GA or
SAHA had greater effects on depletion of Hsp90/Cdc37
client proteins. Figure 5E and 5F shows that 0.2 μMG A
or 1 μM SAHA can enhance the ability of apigenin to
deplete the Cdc37 client kinases, Raf-1, Src and Cdk4.
Apigenin inhibits proliferation, suppresses CK2 activity
and depletes Cdc37 client kinases in CD138
+ cells from
patients with MM
The results reported above demonstrate that apigenin
has a potent ability to suppress CK2 activity, inhibit
Hsp90/Cdc37 chaperone function and induce growth
inhibition and apoptosis in MM cell lines. Next, we
investigated the effects of apigenin on proliferation of
CD138
+ cells from 12 patients with MM (Additional file
1) and normal peripheral blood mononuclear cells
(PBMCs) from 5 healthy donors. CD138
+ cells and
PBMCs were exposed to different concentrations of api-
genin for 24 h and were examined for cell viability by
the MTS assay. The results showed that the CD138
+
Figure 4 Apigenin reduces Cdc37 phosphorylation, disassociates Hsp90/Cdc37/kinase complexes and degrades Hsp90/Cdc37 client
proteins. (A) U266 and RPMI 8226 cells were treated with apigenin or TBB for 24 h. Cdc37 protein was immunoprecipitated from whole cell
lysates (500 μg each) with an anti-Cdc37 antibody and analyzed by immunoblotting with antibodies against phosphoserine, Hsp90, Cdc37, and
Cdk4. For this experiment, 30 μg of the inputs was subjected to western blot to determine the levels of Cdc37, Hsp90, and Cdk4. (B) After
treatment of apigenin for 24 h, the protein levels of Cd37 client kinases (RIP1, Raf-1, Src and Cdk4) in U266 and RPMI 8226 cells were detected
by western blot analysis.
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Page 8 of 14Figure 5 Apigenin-induced proteasome-dependent degradation of Hsp90/Cdc37 client proteins are correlated with inhibition of CK2.
(A) HeLa cells were treated with the indicated concentrations of apigenin or TBB for 24 h. The protein levels of CK2a, RIP1, Raf-1 and Cdk4 were
detected by western blot analysis. (B) HeLa cells were transiently transfected with control siRNA or CK2a siRNA for 48 h. Whole-cell lysates were
analyzed by western blotting using the indicated antibodies. (C) Next, siRNA was introduced intoU266 and RPMI 8226 cells using electroporation.
After 48 h, the cells were harvested to detect the protein levels by western blot. b-actin, as well as a-tubulin, served as loading control. (D) U266
cells were pretreated with MG132 (1 μM) for 1 h, and the cells were subsequently treated with apigenin (90 μM) for an additional 12 h. Whole-
cell lysates were subjected to western blot analysis using antibodies against Raf-1, Src, Cdk4 and b-actin. (E) and (F) U266 cells were incubated
with or without the Hsp90 inhibitor GA (0.2 μM) or SAHA (1 μM) for 24 h in the presence or absence of 30 μM apigenin. Whole-cell lysates were
subjected to western blotting to determine the levels of Raf-1, Src, Cdk4 and b-actin. The bar graphs on the right show the percentage of
intensities of the protein band from each treatment relative to the controls, which were defined as 100%. Values represent the means ± SD.
*Significant difference from the three groups was designed by ANOVA, **p < 0.01.
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apigenin and exhibited a dose-dependent decrease in
cellular viability. Cells from one patient (No. 9) showed
a slight growth inhibition (Figure 6A). All PBMCs sam-
ples were resistant to apigenin, even at higher concen-
trations (Figure 6B). Next, we determined whether the
inhibitory effects of apigenin on proliferation of CD138
+
were correlated with CK2 suppression. CD138
+ and
CD138
- cells from MM patients were treated with 50
μM apigenin for 24h, stained and CK2a protein was
detected by flow cytometry. As shown in Figure 6C,
CD138
- cells with low CK2a expression remained
unchanged, whereas CD138
+ cells with high CK2a
expression decreased obviously after apigenin treatment.
We also detected the change in CK2a expression by
confocal microscopy. Following apigenin exposure for
24 h, 4 out of 5 patients showed various degree of
decreased staining for CK2a in CD138
+ cells. Staining
of CD138
+ cells from patient No. 9 was slightly
decreased, whereas the staining of PBMC samples was
unchanged (Figure 6D), which is consistent with a pre-
v i o u sr e p o r t[ 6 ] .W ea l s ou s e dC D 1 3 8a n dC K 2 a or a-
tubulin and CK2a double staining to confirm that the
decline of CK2a staining was specific. As shown in Fig-
ure 6E, apigenin only induced a reduction in CK2a
staining, but did not affect the staining of CD138 or a-
tubulin (data not shown). The fluorescence intensity of
each sample following apigenin treatment was analyzed
by the softWoRx explorer software and the changes in
CK2a staining in each sample are shown in Figure 6F.
To further confirm that the apigenin-induced inhibitory
effect of CD138
+ MM cells was correlated with suppres-
sion of CK2, CD138
+ cells from patient No. 8 and No. 9
were further analyzed for CK2 kinase activity. As shown
in Figure 6G, apigenin treatment inhibited CK2 activity
to a greater extent in CD138
+ cells from patient No. 8
than in cells from patient No. 9. Taken together, these
results showed that the apigenin-induced decrease in
CK2a staining correlated with the decrease in CK2
kinase activity in different samples. Western blot analy-
sis further demonstrated that apigenin induced a
decrease in the CK2a and Cdc37 client proteins Raf-1,
Src and Cdk4 in CD138
+ cells that was similar to the
reduction observed in MM cell lines (Figure 6H).
Discussion
In this study we have shown that a natural dietary flavo-
noid, apigenin, inhibited the proliferation of MM cell
lines and primary MM cells, arrested cell cycle progres-
sion, and induced programmed cell death. We demon-
s t r a t e dt h a ta p i g e n i ni n h i b ited CK2 activity, thereby
leading to inactivation of multiple kinases, including the
constitutive and inducible STAT3, AKT, ERK, IBa n d
their upstream kinase partners PDK, MEK and IKK.
Apigenin also downregulated antiapoptotic Bcl-2 family
proteins and IAP proteins. We have also shown that the
inhibition of CK2-mediated Cdc37 phosphorylation dis-
rupted the Hsp90/Cdc37 chaperone function and led to
the degradation of multiple Hsp90/Cdc37 client proteins
via the proteasome pathway, which may be the primary
mechanism mediating the anticancer activities of
apigenin.
Although it is known that apigenin has a selective
inhibitory effect on CK2, it has not known if apigenin
kills cancer cells through its capacity to interfere with
Cdc37 phosphorylation and to disrupt Hsp90 chaperone
function. As had been previously reported [6], we
observed that primary MM cells and all MM cell lines
express constitutively activated CK2. We found that
treatment with apigenin downregulated kinase activity
in both MM cell lines and the primary MM cells, con-
firming the suppression of CK2 (Figure 1, Figure 6). In
MM cells, the ability of apigenin to inhibit cell prolifera-
tion and to induce cell death correlated with its ability
to inhibit CK2 activity. It was previously reported that
highly CK2a-positive leukemia cells are more sensitive
to apigenin-induced cell death than are CK2a leukemia
cells with relatively low levels of CK2a [21]. However,
in this study, we observed that the sensitivity of MM
cells to apigenin-induced cell death depended on
whether apigenin effectively inhibited CK2 kinase activ-
ity, decreased CK2a protein levels, decreased the phos-
phorylation of Cdc37 and induced the degradation of
Hsp90/Cdc37 client kinases. Consistent with these
observations, one of the primary MM cell samples in
our analysis (No. 9) exhibited high CK2a expression but
had low sensitivity to apigenin, whereas the CK2a low
U266 cells were more sensitive to apigenin than CK2a
high RPMI 8226 cells. We are currently investigating
possible explanations for the failure of apigenin to sup-
press CK2 activity in particular MM cells.
Importantly, apigenin did not inhibit CK2 activity or
exhibit any cytotoxic effects in PBMCs (Figure 6). Api-
genin-mediated suppression of CK2 activity was accom-
panied by reduced phosphorylation of Cdc37 in MM
cells, leading to the disassociation of Hsp90/Cdc37/cli-
ent protein complexes and inducing the degradation of
client kinase proteins including RIP1, Raf-1, Src, Cdk4,
and AKT via the ubiquitin-proteasome pathway (Figure
4, 5, 6). Since some kinases, such as RIP1, Raf-1 and
Src, locate at the upstream of various signal pathways,
the degradation of these kinase proteins could lead to
the abrogation of their downstream pathways. These
findings help to explain how apigenin can inhibit many
signaling pathways. In addition to apigenin, resveratrol
and epigallocatechin-3-gallate (EGCG) have been
reported to induce apoptosis by significantly downregu-
lating CK2 activity in both ALVA-41 and PC-3 prostate
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Page 10 of 14Figure 6 Apigenin inhibits proliferation, down-regulates CK2 activity, and depletes Hsp90/Cdc37 client proteins in primary MM cells.
(A) Enriched CD138
+ cells from 12 multiple myeloma patients were prepared by immunomagnetic bead selection. After treatment of apigenin
for 24 h, cell viability was measured by the MTS assay as described in Material and Methods. Values represent the mean ± SD. *Significant
difference from control. *p < 0.05, **p < 0.01. (B) PBMCs were treated with the indicated concentrations of apigenin for 24 h and the cell
viability was measured by MTS assays. (C) After treatment with apigenin for 24 h, the expression of CK2a in CD138 negative and positive cells
was analyzed by flow cytometry and quantified using the mean fluorescence intensity. (D) After treatment with or without 50 μM apigenin for
24 h, PBMCs and the enriched primary myeloma cells were examined by immunofluorescence microscopy to detect the levels of CK2a. The bar
is equal to 5 μm. (E) The CD138
+ cells were treated with apigenin for 24 h and were stained for CK2a (green), CD138 antigen (red) and DNA
(blue). The bar, 5 μm. (F) The fluorescence intensity of each sample from (D) was analyzed using the softWoRx Explorer software. The average
pixel intensities from 30 cells of three different fields in each group were measured, and background pixel intensities were subtracted. Values
represent the mean ± SD of at least 3 measurements. * Significant difference from control cells, **p < 0.01. (G) After treatment of apigenin for 24
h, the CK2 kinase activity in primary MM cell purified from patient No. 8 and No. 9 was analyzed. *Significant difference from control cells, *p <
0.05, **p < 0.01. (H) Purified PBMC or enriched CD138
+ cells from MM patients were treated with apigenin for 24 h, and the whole-cell lysates
were subjected to western blotting to determine the levels of CK2a, Raf-1, Src, Cdk4 and b-actin.
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Page 11 of 14cancer cells [27]. Bioactive polyphenolic and flavonoid
compounds have demonstrated potential in cancer ther-
apy and cancer chemoprevention, and further studies
are needed to determine if CK2 is the common target of
these compounds. The possibility that Cdc37 is a sec-
ondary target also requires further assessment.
Among the kinases affected by apigenin treatment,
receptor interacting protein 1 (RIP1) is of special inter-
est. It has not been determined if RIP1 is a Cdc37 client
kinase, but it has been shown that the stability of RIP1
is dependent on Hsp90 chaperone function [28]. Recent
studies have demonstrated that RIP1 kinase is a key pro-
tein in the cellular decision of cells to live or die upon
exposure to different stress signals [29]. Depending on
the cellular context and stimulation, RIP1 kinase may
participate in three different signal complexes, which
have various functions with respect to mediating the
activation of NF-B, apoptosis, or necroptosis [30,31].
Recent studies have reported that apigenin functions as
either a pro-apoptotic or anti-apoptotic mediator via
suppression of NF-B activation in malignant cells, such
as in pancreatic cancer cells [32] and in various models
of inflammation including T cell resistance to activa-
tion-induced cell death [33], lipopolysaccharide-stimu-
lated monocytes and macrophages [34], and pancreatic
beta-cells [35]. Depletion of the RIP1 protein may be an
important mechanism by which apigenin inhibits NF-B
activation to mediate various functions.
The resistance of MM cells to apoptosis involves high
expression of members of the Bcl-2 family. These antia-
poptotic proteins protect against permeabilization of the
mitochondrial outer membrane. The combined total level
of Bcl-2, Bcl-xL, and Mcl-1 in the outer membrane deter-
mines the resistance of cells to apoptosis [36,37]. In this
work, we have shown that apigenin can downregulate
multiple antiapoptotic proteins, including Mcl-1, XIAP,
Survivin, Bcl-2 and Bcl-xl (Figure 2). Compared with other
antiapoptotic proteins, Mcl-1 plays a more important role
in the aberrant survival of MM cells [37,38]. As an antia-
poptotic protein, Mcl-1 functions either by sequestering
Bak on the outer mitochondrial membrane or by heterodi-
merizing with activated BH3-only proteins including tBid,
PUMA, and Bim [39]. Normally, Mcl-1 is constitutively
expressed in many MM cells [40,41]. Various extra-cellu-
lar stimuli, including interleukins, growth factors, 12-O-
tetradecanoyl-phorbol 13-acetate (TPA) and IFN, can
upregulate Mcl-1 expression via activation through differ-
ent signaling pathways [42,43]. Previous studies have
shown that down-regulation of Mcl-1 by antisense oligo-
nucleotides is sufficient to induce apoptosis in MM cells
and to enhance cancer cell sensitivity to TRAIL, suggest-
ing that Mcl-1 might be a potential therapeutic target for
the treatment of several human malignancies, including
MM [37,44]. In MM, tumor cells accumulate within the
bone marrow by binding to the extracellular matrix pro-
teins and bone marrow stromal cells (BMSCs). The inter-
action between MM cells and BMSCs induces secretions
of various interleukins and growth factors by both cells to
promote MM development. Among these interleukins is
IL-6, which then triggers VEGF secretion [45]. Although
IL-6 and VEGF activate multiple signaling pathways,
including Jak-STAT3, ERK and PI3K/AKT, the upregula-
tion of Mcl-1 expression is their main mechanism of med-
iating survival and proliferation in MM cells [46]. Ideally,
the IL-6/VEGF loop ideally supports MM cell growth
within the BM microenvironment. A previous study has
shown that apigenin can inhibit the expression of VEGF
[47]. In the current study, we have demonstrated that api-
genin not only suppresses constitutively activated STAT3,
ERK, AKT and NF-B, but it also blocks exogenous IL-6-
induced activation of STAT3, and inhibits IGF-1-induced
activation of AKT and ERK. These survival signals are
important for initiating transcription of Mcl-1 and other
antiapoptotic proteins and for maintaining their stability
[42]. The inhibitory effect of apigenin may be indirect, as
many upstream kinases, such as MEK and IKK, were inac-
tivated as well. The ability of apigenin to suppress consti-
tutive and inducible signaling pathways and to
downregulate Mcl-1 also contributes to its cytotoxicity in
MM cells.
Conclusion
Apigenin exhibited anticancer activity against MM cells
in vitro. Apigenin decreased Cdc37 phosphorylation by
inhibiting CK2 kinase activity, thereby resulting in the
disassociation of Hsp90/Cdc37/client complexes and the
degradation of Hsp90 client kinase proteins. The deple-
tion of kinases leads to suppression of multiple constitu-
tive and inducible signaling pathways, downregulation of
Mcl-1 and induction of apoptosis.
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